Strategic focus TuHURA is a Phase 3 immuno-oncology company targeting resistance to cancer immunotherapy, presenting a compelling opportunity to position companion diagnostic services, clinical trial support, and biomarker collaboration with oncology teams advancing checkpoint inhibitors and cellular therapies.

Pipeline expansion The company is advancing TBS-2025 a VISTA inhibiting monoclonal antibody into Phase 1b/2 in mutNPM1 r/r AML, plus plans for antibody-drug conjugates targeting MDSCs, offering potential for collaborations on translational research, manufacturing partnerships, and trial sponsorships.

Clinical trials With ongoing dose escalation opportunities and a focus on novel immune-oncology platforms, TuHURA may seek strategic manufacturing, CRO/CDMO partnerships, and data-generation collaborations to accelerate trial timelines and regulatory milestones.

Financial readiness Despite a small to mid-size footprint, current funding of 47M and early revenue, combined with NASDAQ listing, positions TuHURA for co-development or milestone-based deals with large pharma seeking innovative IO assets to diversify portfolios.

Industry positioning As a niche player focused on overcoming resistance to immunotherapies, TuHURA can be paired with larger oncology franchises by offering access to its Delta Opioid Receptor technology and innate immune agonists, enabling collaboration around combination therapies and accelerated go-to-market strategies.